A cytotoxic drug composed of IL-13 and a modified bacterial toxin, Pseudomonas exotoxin 38 (IL-13-PE38), has been developed for GBM therapy, as up to 80% of cases of GBMs show overexpression of IL-13Rα2 [27]. Here, IL13RA2 is linked to glioblastoma.